Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients

Table 1 Clinical and pathological characteristics of breast cancer patients

Patient	Menopause status	Histologic type	Histological grading	B classification	MIB-1 [%]	Receptor status			Molecular subtype
Patient	Menopause status	Histologic type	Histological grading	B classification	MIB-1 [%]	ER	PR	HER2/neu	Molecular subtype
1	Post	IDC	G2	B5b	10	+++	++	−	Luminal A
2	Post	IDC	G2	B5b	10	+++	++	−	Luminal A
3	Peri	IDC	G3	B5b	30	+++	−	−	Luminal A
4	Pre	IDC	G2	B5b	40	+++	++	+++	Luminal B
5	Post	IDC	G2	B5b	60	+++	++	−	Luminal A
6	Pre	IDC	G3	B5b	50	+++	+++	+++	Luminal B
7	Post	IDC	G3	B5b	20	pos.	pos.	−	Luminal A
8	Post	IDC	G2	B5b	20	+++	+++	−	Luminal A
9	Post	IDC	G3	B5	30	++	+++	−	Luminal A
10	Post	IDC	G3	B5b	20	+++	+++	+	Luminal B
11	Post	IDC	G1	B5c	20	+++	+++	+	Luminal B
12	Post	IDC	G3	B5b	70	−	−	−	Triple negative
13	Pre	ILC	n.s.	B5b	50	+++	++	−	Luminal A
14	Pre	IDC	G3	B5b	80	++	−	−	Luminal A
15	Post	IDC	G3	B5b	40	+++	++	−	Luminal A
16	Post	ILC	G2	B5b	30	+++	+++	−	Luminal A
17	Pre	Mucinous	G2	B5b	50	+++	++	+++	Luminal B
18	Post	IDC	G3	B5b	50	−	−	+++	HER2/neu

IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, MIB-1 mindbomb E3 ubiquitin protein ligase 1 (proliferative activity), ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growth factor receptor 2, n.s. not specified, + weakly positive, ++ moderately positive, +++ strongly positive, − negative

ISSN: 1471-2407